Search Results 171-180 of 11740 for ���������������������������:za33���24������ ������������������������ ������

  1. Liver transplant - Doctors & Departments - Mayo Clinic

    24, 2021. Liver transplantation. Merck Manual Professional Version. https://www.merckmanuals.com/professional/immunology-allergic-disorders/transplantation/ ...

  2. A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies (ERADIC8) - Mayo Clinic

    Jacksonville, Florida: 24-009952; Rochester, Minnesota: 24-009952; Scottsdale/Phoenix, Arizona: 24-009952. NCT ID: NCT06395519. Sponsor Protocol Number: ETX ...

  3. https://www.mayoclinic.org/spanish_condition_consolidated_concepts.xml

  4. Clinical trials - Oncology (Medical)

    The purpose of this study is to assess the 24-week grade 3/4 keratopathy-free rate of an alternative dose/dosing schedule for belantamab mafodotin in ...

  5. Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors - Mayo Clinic

    PRI-724 dosing is to start at 40 mg/m2/day, CIV infusion over 24 hours × 7 days. Phase Ib: This phase is to begin upon identification of the MTD in Phase 1a ...

  6. Whipple procedure - Doctors & Departments - Mayo Clinic

    Accessed March 24, 2023. Reber HA. Surgical resection of lesions of the head of the pancreas. https://www.uptodate.com/contents/search. Accessed March 24, 2023.

  7. Deb Balzer | Mayo Clinic News Network - Page 22 of 72

    Marcie Billings, a Mayo Clinic pediatrician, says 1 in 5 youth will[...] By Deb Balzer • May 24, 2022. Questions ...

  8. A Study to Evaluate Intravenous Erenumab in Patients with Status Migrainosus - Mayo Clinic

    ... 24 hours, and to evaluate late endpoints of response including change in migraine days at 4 weeks compared to baseline report, change in headache days at 4 ...

  9. PKD1 Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease - Mayo Clinic

    Rochester, Minnesota: 24-008357. Sponsor Protocol Number: VX24-KDO-901. About this study. The purpose of this study is to estimate the prevalence of PKD1 ...

  10. A Study To Evaluate The Safety, Effectiveness And Tolerable Dose Of BMS-986393 In Novel Combinations In Participants With Relapsed And/or Refractory Multiple Myeloma - Mayo Clinic

    Jacksonville, Florida: 24-004039; Scottsdale/Phoenix, Arizona: 24-004039. NCT ID: NCT06121843. Sponsor Protocol Number: CA0881005. About this study. The ...